Clinical Trial Update: ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ABX-EGF (panitumumab)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Amgen | Conditions: Non-Small Cell Lung Cancer, Neoplasm Metastasis | Phase 2 | Status: COMPLETED